{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:07:51Z","timestamp":1779163671458,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003896","name":"Henry M. Jackson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["CDMRPL-19-0-PR180876"],"award-info":[{"award-number":["CDMRPL-19-0-PR180876"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XH-19-0-0020"],"award-info":[{"award-number":["W81XH-19-0-0020"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.vaccine.2025.127832","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:37:58Z","timestamp":1760247478000},"page":"127832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunogenicity of HLA-restricted peptide vaccine candidates delivered by self-assembling protein nanoparticle (SAPN) technology"],"prefix":"10.1016","volume":"66","author":[{"given":"Maria","family":"Belmonte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwadwo Asamoah","family":"Kusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Kyei-Baafour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebenezer Addo","family":"Ofori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Burkhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelina","family":"Angov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Matyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pfeffer-Kleemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Storey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pharath","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnel","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harini","family":"Ganeshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Villasante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Sedegah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2025.127832_bb0005","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1016\/S2666-5247(24)00016-8","article-title":"The 2023 WHO world malaria report","volume":"5","author":"Venkatesan","year":"2024","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127832_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12936-024-04847-9","article-title":"Presence and abundance of malaria vector species in Miami-Dade County, Florida","volume":"23","author":"Wilke","year":"2024","journal-title":"Malar J"},{"issue":"10399","key":"10.1016\/j.vaccine.2025.127832_bb0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(23)01569-6","article-title":"Climate change and malaria: predictions becoming reality","volume":"402","author":"Samarasekera","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127832_bb0020","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1073\/pnas.1302089111","article-title":"Impact of climate change on global malaria distribution","volume":"111","author":"Caminade","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127832_bb0025","doi-asserted-by":"crossref","DOI":"10.1098\/rsbl.2022.0365","article-title":"Rapid range shifts in African Anopheles mosquitoes over the last century","volume":"19","author":"Carlson","year":"2023","journal-title":"Biol Lett"},{"key":"10.1016\/j.vaccine.2025.127832_bb0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12936-016-1302-x","article-title":"The need for operational research and capacity-building in support of the Global Technical Strategy for Malaria 2016\u20132030","volume":"15","author":"Ramsay","year":"2016","journal-title":"Malar J"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127832_bb0035","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ Vaccine","volume":"2","author":"Epstein","year":"2017","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127832_bb0040","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka","year":"2016","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.vaccine.2025.127832_bb0045","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-Year Efficacy of RTS,S\/AS01 Malaria Vaccine among Young African Children","volume":"374","author":"Olotu","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127832_bb0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156588","article-title":"S: the first malaria vaccine","volume":"132","author":"Zavala","year":"2022","journal-title":"J Clin Invest"},{"issue":"52","key":"10.1016\/j.vaccine.2025.127832_bb0055","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1016\/j.vaccine.2015.09.061","article-title":"RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap","volume":"33","author":"Kaslow","year":"2015","journal-title":"Vaccine"},{"issue":"10426","key":"10.1016\/j.vaccine.2025.127832_bb0060","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127832_bb0065","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127832_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163026","article-title":"Vaccine strain-specificity of protective HLA-restricted class 1 P. falciparum epitopes","volume":"11","author":"Sedegah","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127832_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038898","article-title":"Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults","volume":"7","author":"Remarque","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127832_bb0080","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4049\/jimmunol.166.1.481","article-title":"A totally synthetic polyoxime malaria vaccine containing plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types","volume":"166","author":"Nardin","year":"2001","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127832_bb0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.20101488","article-title":"The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host","volume":"208","author":"Coppi","year":"2011","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127832_bb0090","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1074\/jbc.M311331200","article-title":"A role for apical membrane antigen 1 during invasion of hepatocytes by plasmodium falciparum sporozoites","volume":"279","author":"Silvie","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127832_bb0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pt.2018.11.008","article-title":"Important Extracellular Interactions between Plasmodium Sporozoites and Host Cells Required for Infection","volume":"35","author":"Dundas","year":"2019","journal-title":"Trends Parasitol"},{"issue":"17","key":"10.1016\/j.vaccine.2025.127832_bb0100","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.1073\/pnas.1633254100","article-title":"Identification of plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data","volume":"100","author":"Doolan","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127832_bb0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.vaccine.2021.12.042","article-title":"Towards large-scale identification of HLA-restricted T cell epitopes from four vaccine candidate antigens in a malaria endemic community in Ghana","volume":"40","author":"Kusi","year":"2022","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127832_bb0110","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.vaccine.2023.01.016","article-title":"Immunodominant T cell peptides from four candidate malarial antigens as biomarkers of protective immunity against malaria","volume":"41","author":"Belmonte","year":"2023","journal-title":"Vaccine"},{"issue":"D1","key":"10.1016\/j.vaccine.2025.127832_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1092","article-title":"The immune epitope database (IEDB): 2024 update","volume":"53","author":"Vita","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127832_bb0120","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1586\/14760584.2015.1096781","article-title":"Malaria vaccine based on self-assembling protein nanoparticles","volume":"14","author":"Burkhard","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"31","key":"10.1016\/j.vaccine.2025.127832_bb0125","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1016\/j.vaccine.2017.05.070","article-title":"Liposomes containing monophosphoryl lipid a and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013","volume":"35","author":"Genito","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127832_bb0130","first-page":"39","article-title":"Comparative testing of monoclonal antibodies against plasmodium falciparum sporozoites for ELISA development","volume":"65","author":"Wirtz","year":"1987","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127832_bb0135","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bpj.2015.10.057","article-title":"Principles governing the self-assembly of coiled-coil protein nanoparticles","volume":"110","author":"Indelicato","year":"2016","journal-title":"Biophys J"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127832_bb0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.nano.2006.04.007","article-title":"Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles","volume":"2","author":"Raman","year":"2006","journal-title":"Nanomedicine"},{"issue":"4706","key":"10.1016\/j.vaccine.2025.127832_bb0145","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2409595","article-title":"Rationale for development of a synthetic vaccine against plasmodium falciparum malaria","volume":"228","author":"Zavala","year":"1985","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127832_bb0150","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S\/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127832_bb0155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127832_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00083-1","article-title":"R21 in matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study","volume":"6","author":"Venkatraman","year":"2025","journal-title":"Lancet Microbe"},{"issue":"9988","key":"10.1016\/j.vaccine.2025.127832_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Rts SCTP","year":"2015","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.vaccine.2025.127832_bb0170","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic Diversity and Protective Efficacy of the RTS,S\/AS01 Malaria Vaccine","volume":"373","author":"Neafsey","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127832_bb0175","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/infdis\/jis709","article-title":"Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications","volume":"207","author":"Ouattara","year":"2013","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2025.127832_bb0180","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.1073\/pnas.95.13.7648","article-title":"Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine","volume":"95","author":"Sedegah","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"41","key":"10.1016\/j.vaccine.2025.127832_bb0185","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1016\/j.vaccine.2017.02.040","article-title":"Development of a self-assembling protein nanoparticle vaccine targeting plasmodium falciparum Circumsporozoite protein delivered in three Army liposome formulation adjuvants","volume":"35","author":"Seth","year":"2017","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127832_bb0190","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.vaccine.2017.12.001","article-title":"Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine","volume":"36","author":"Kaba","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127832_bb0195","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1475-2875-12-136","article-title":"Mechanisms of protective immune responses induced by the plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine","volume":"12","author":"McCoy","year":"2013","journal-title":"Malar J"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127832_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106241","article-title":"Sterile immunity to malaria after DNA prime\/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes","volume":"9","author":"Sedegah","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127832_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0318098","article-title":"Human responses to the DNA prime\/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC class I-restricted epitopes","volume":"20","author":"Ganeshan","year":"2025","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127832_bb0210","article-title":"Orientation of Antigen Display on Self-Assembling Protein Nanoparticles Influences Immunogenicity","volume":"9","author":"Schneider","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127832_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73210-0","article-title":"Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice","volume":"10","author":"El Bissati","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127832_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276241","article-title":"Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection","volume":"17","author":"Sedegah","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127832_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-7580-5-3","article-title":"Of mice and humans: how good are HLA transgenic mice as a model of human immune responses?","volume":"5","author":"Kotturi","year":"2009","journal-title":"Immunome Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:28:11Z","timestamp":1778542091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25011296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"alternative-id":["S0264410X25011296"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127832","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of HLA-restricted peptide vaccine candidates delivered by self-assembling protein nanoparticle (SAPN) technology","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127832"}}